论文部分内容阅读
目的:探讨抗CD33单抗吉妥单抗治疗由复发难治急性髓系白血病（RR-AML）转化的混合表型急性白血病（MPAL）患者的效果及预后。方法:回顾性分析苏州大学附属第一医院诊治的1例由RR-AML转化的MPAL（B淋系和髓系双表型）患者的临床资料，并复习相关文献。结果:该患者采用吉妥单抗3 mg/mn 2第1、5、9天联合三尖杉酯碱、小剂量阿糖胞苷及VP（长春新碱、泼尼松）方案化疗，获得第2次完全缓解（CR2）后桥接异基因造血干细胞移植（allo-HSCT）。吉妥单抗联合化疗后，患者骨髓形态达CR2，流式细胞术检测CD33抗原由高表达（>99.5%）转为阴性表达。随访至2020年4月，无复发生存时间为22个月，总生存时间接近27个月。n 结论:抗CD33单抗辅助治疗CD33高表达的MPAL效果确切，预后良好，但仅为个例。个体化联合给药方案等问题仍需进一步积累经验及临床试验。“,”Objectives:To investigate the efficacy and prognosis of anti-CD33 monoclonal antibody gemtuzumab ozogamicin in the treatment of patients with mixed-phenotype acute leukemia (MPAL) transformed from relapsed/refractory acute myeloid leukemia (RR-AML).Methods:The clinical data of one patient with MPAL (B lymphoid and myeloid biphenotype) transformed from RR-AML diagnosed and treated in the First Affiliated Hospital of Soochow University were retrospectively analyzed, and the related literature was reviewed.Results:The patient was treated with gemtuzumab ozogamicin 3 mg/mn 2 on day 1, 5, and 9 combined with harringtonine, low-dose cytarabine and VP (vincristine, prednisone) regimen chemotherapy. After achieving the second complete remission (CR2), the patient was bridged with allogeneic hematopoietic stem cell transplantation (allo-HSCT). After the treatment of gemtuzumab ozogamicin combined with chemotherapy, the bone marrow morphology of the patient reached CR2, and the CD33 antigen detected by flow cytometry changed from high expression (>99.5%) to negative expression. A follow-up until April 2020 showed that the recurrence-free survival time was 22 months, and the overall survival time was close to 27 months.n Conclusions:The anti-CD33 monoclonal antibody is effective in adjuvant treatment of MPAL with high expression of CD33 and has a good prognosis, but it is only a single case. Issues such as individualized combined dosing regimens still require further accumulation of experience and clinical trials.